238 results about "Treatment medication" patented technology

The present invention provides a novel therapeutic drug for treating a Prom1-associated retinal disease. Specifically, the present invention provides an optimized Prom1 gene expression cassette, an rAAV viral vector, and a gene therapy drug. The drug of the present invention can specifically express the PROM1 protein in the retinal photoreceptor layer, and is suitable for the clinical treatment of a retinal disease associated with Prom1 gene mutation.

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The invention discloses a preparation method of a cochlear organ chip integrated with a blood labyrinth barrier, and belongs to the field of biomedical engineering. The preparation method of the simulated blood labyrinth barrier comprises the following steps: constructing an endothelial cell culture cavity and a pericyte culture cavity, and separating the endothelial cell culture cavity and the pericyte culture cavity through a simulated basement membrane; and respectively inoculating percutaneous cells and endothelial cells into a percutaneous cell culture cavity and an endothelial cell culture cavity, and culturing to obtain the simulated blood lost barrier. The chip can effectively simulate the structure and the function of the BLB, and the barrier integrity of the BLB is evaluated through TEER (trans-epithelial electrical resistance) measurement and an apparent permeability coefficient. The invention also relates to application of the chip in NIHL drug screening, in particular to drug evaluation for oxidative stress induced inner ear organ injury. Through the platform, the protection effect of the candidate drugs on the TBHP-induced oxidative stress injury of the inner ear organs can be evaluated, and a new tool and thought are provided for developing novel NIHL treatment drugs.

The invention provides a novel therapeutic drug for treating Prom1 related retinal diseases. Specifically, the invention provides an optimized Prom1 gene expression cassette, an rAAV virus vector and a gene therapy drug. The medicine provided by the invention can specifically express the PROM1 protein in a retina photoreceptor layer, and is suitable for clinical application to treatment of Prom1 gene mutation related retinal diseases.

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.

The invention discloses a multi-stage leaching purification method of a targeted therapeutic drug. The multi-stage leaching purification method comprises the following steps: sequentially filling an adsorption column with a porous organic polymer layer and an adsorption ball layer; controlling the flow rate of the leacheate and the column temperature for leaching, and setting an adsorption saturation threshold value; carrier gas is adopted to heat and desorb the porous polymer layer, and carrier gas components are switched to heat and desorb the adsorption ball layer; the method comprises the following steps: introducing carrier gas carrying iodine vapor into an alkaline absorption tower to treat waste gas, eluting impurities of adsorption balls by adopting an acidic mixed solution, and performing catalytic degradation by combining ultraviolet light; a chelating agent solution is used for regenerating adsorption balls, a silver salt solution is used for heavily loading silver ions, an organic solvent is used for eluting and regenerating a porous polymer, regular calibration and part replacement are conducted on a system, and organic pollutants and radionuclides in a matrix are difficult to treat synchronously through a traditional single-layer adsorption material; according to the leaching purification method, the generation amount of radioactive waste liquid is remarkably reduced, and meanwhile the shielding protection requirement of the follow-up purification step is reduced.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The invention discloses application of a compound AZD5718 in preparation of a medicine for preventing and / or treating cholestatic liver diseases, and belongs to the field of biological medicines. The compound AZD5718 can effectively improve hepatocyte damage and bile metabolism disorder caused by Mdr2 gene deletion, provides solid experimental data support for developing novel drugs for treating cholestatic liver diseases, is expected to provide differentiated therapeutic drug choices for clinic, and has important medical value and social significance.

The application discloses a kind of elastin-like polypeptide V 20 K 40 L, mRNA vaccine and preparation method and application in preparation tumor prevention, mitigation or treating drug.The elastin-like polypeptide carrier V 20 K 40 L provided by the application has good biocompatibility, and has no adverse reaction in vivo.The elastin-like polypeptide V 20 K 40 L provided by the application has amphiphilic structure, can be loaded Melan-A mRNA by hydrophobic self-assembly and electrostatic adsorption, and is in the state of shrinkage when higher than Tt temperature, which can prevent the uncontrollable leakage of mRNA.Furthermore, V 20 K 40 L contains lysosome escape peptide, which can further improve the transfection efficiency of mRNA by promoting lysosome escape.The elastin-like polypeptide V 20 K 40 L in the application can deliver Melan-A mRNA efficiently and safely, and realize the prevention and treatment of melanoma.

The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.

This invention discloses a method for preparing and applying a photothermal nanoreagent targeting bacteria. This invention utilizes Ti3C2T... x Using MXene as a matrix, a photothermal nanoreagent MXene@PDA@Peptide (MPP) was constructed by sequentially modifying the surface of Ti3C2Tx MXene with polydopamine and grafting it with the peptide CAEKA, which has the function of recognizing bacteria. Under the recognition of the peptide CAEKA, the photothermal Ti3C2Tx MXene was targeted. x MXene nanosheets are guided to the surface of bacterial cells, achieving effective sterilization at a relatively low overall temperature of around 50°C (or achieving more efficient sterilization at the same overall temperature level, exhibiting superior sterilization performance compared to pure Ti3C2Tx MXene). This makes them particularly suitable for the preparation of therapeutic drugs for subcutaneous abscesses caused by methicillin-resistant Staphylococcus aureus (MRSA) infection.

The invention discloses a protein ADGRE2-targeted acute myelogenous leukemia treatment medicine and application, and relates to the technical field of biomedicine. The invention provides an application of a drug targeting protein ADGRE2 in preparation of a drug for preventing and / or treating acute myelogenous leukemia. The protein ADGRE2 is highly specifically expressed on the surface of an acute myelogenous leukemia cell membrane, and the targeted protein ADGRE2 can inhibit the proliferation ability and migration ability of acute myelogenous leukemia cells and promote the apoptosis of the acute myelogenous leukemia cells. Meanwhile, the protein ADGRE2 can be used as an effective drug target for CAR-T cell therapy, guides the development of novel CAR-T cells, and is expected to promote the novel target CAR-T cell therapy for acute myelogenous leukemia to make a major breakthrough.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The invention discloses a traditional Chinese medicine composition for scalds and burns as well as preparation and application thereof, and belongs to the technical field of traditional Chinese medicine treatment. The traditional Chinese medicine composition is prepared by combining raw materials including barks of barks of portulaca oleracea, barks of rubus corchorifolius, carbon crystals (coal crystals) and borneol according to a specific weight ratio, and raw tung oil is used as a matrix carrier. The preparation process is completed through the steps of raw material purification, drying, nanoscale crushing, precise proportioning, mixing and screening and the like, and the product is fine and uniform nanoscale powder. The traditional Chinese medicine composition is scientific and reasonable in formula, simple and controllable in preparation process and convenient and safe in medication mode, solves the problems of slow healing, obvious scars, easy infection, large side effects and the like of existing scald and burn treatment medicines, is suitable for various scenes such as family emergency, clinical medical treatment and outdoor operation, and has extremely high popularization and application values.

The invention discloses an application of R-3-hydroxybutyric acid (R-3-hydroxybutyric acid, 3HB) or a derivative of the R-3-hydroxybutyric acid in delaying and preventing light aging of skin. Experiments prove that the 3HB or the derivative thereof can remarkably improve the skin appearance of a mouse with photoaged skin, improve the antioxidant capacity of skin tissue, remarkably recover the thickness of the epidermal layer and the corium layer of the skin, maintain the collagen content in the skin, reduce the denaturation degree of elastic fibers in the skin and improve the skin aging resistance of the mouse. The obvious effect of delaying and preventing the skin photoaging is achieved. The invention provides a novel skin aging treatment medicine or cosmetic candidate compound which has a wide clinical application prospect and good social and economic benefits.

The present invention is directed to an antioxidant ophthalmic emulsion. More particularly, the present invention is directed to an ophthalmic emulsion having a unique combination of ingredients that promotes the transparent property of small oil droplets within the emulsion and promotes the therapeutic delivery capability of the emulsion.

The application discloses application of Ligusticum sinense alcohol extract in preparation of a medicine for preventing or treating drug-induced liver injury, and relates to the technical field of biological medicine.The application proves for the first time that the Ligusticum sinense alcohol extract has an obvious effect of improving acute drug-induced liver injury, can obviously improve serum biochemical indexes, inflammatory factor levels, and liver tissue pathological states of mice with acute drug-induced liver injury, and improve superoxide dismutase (SOD) and glutathione (GSH) activities in liver tissue and reduce malondialdehyde (MDA) and reactive oxygen species (ROS) levels.The pharmacodynamics test proves that the Ligusticum sinense alcohol extract has a significant liver injury protection effect, and has a low effective dose and no toxic side effect.Therefore, the application can become an alternative medicine for preventing and treating drug-induced liver injury.

This invention discloses a wearable ultrasound delivery device for treating otitis media, comprising a wearable main body with a flexible structure adapted to the shape of the patient's ear canal, and a through-hole central channel; an ultrasound drug delivery device, detachably disposed within the central channel, comprising a drug carrier for carrying the therapeutic drug to be delivered, an ultrasound transducer assembly for providing an ultrasound-guided drug delivery mode, and a handheld controller for adjusting the millimeter-level displacement of the drug carrier into the middle ear cavity; wherein, the ultrasound transducer assembly comprises a flexible substrate and multiple piezoelectric transducer units integrated on the flexible substrate, the multiple piezoelectric transducer units constituting a phased array transducer array. This device solves the technical problems of inaccurate drug delivery, low drug delivery efficiency, inability to adapt to the ear canal structure, and complex operation in the prior art.

The application discloses a kind of self-assembly hydrogel, preparation method and application, belong to material field.The application claims to protect a kind of self-assembly hydrogel, it is formed by glycyrrhizic acid, five gallate glucose and paeonol by molecular self-assembly;Wherein, the mass ratio of glycyrrhizic acid and five gallate glucose, paeonol is (10~60) :(1~8) :(2~8).The self-assembly hydrogel provided by the application is suitable for skin, raw material is natural, biocompatibility is good, mechanical and storage stability is excellent, can release paeonol and the transdermal effect is good, three components synergistically improve atopic dermatitis and other skin inflammation, and clinical value is high.In addition, the preparation process of the self-assembly hydrogel of the application is simple, can be prepared using conventional one-pot method, easy to produce.Therefore, the self-assembly hydrogel of the application has the prospect of developing into paeonol sustained-release delivery system, paeonol transdermal sustained-release preparation or skin inflammation treatment drug.

To provide an immunostimulatory bacterial delivery platform and its use for delivery of therapeutic products.SOLUTION: Provided are immunostimulatory bacteria containing genomic modifications and plasmids encoding one or more therapeutic products, e.g., an anti-cancer therapeutic agent or a related treatment. The genome modification results in the immunostimulatory bacteria accumulating in tumor resident immune cells within the tumor microenvironment, where the encoded therapeutic product is expressed. The immunostimulatory bacteria provided herein encode one or more of the complementation products that stimulate, induce or result in a robust anti-cancer response in a subject.SELECTED DRAWING: Figure 1

The invention discloses a cat parvovirus VP2 protein nano antibody as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the cat parvovirus VP2 protein nano antibody is as shown in SEQ ID NO. 1 or SEQ ID NO. 2. According to the invention, an alpaca is immunized by using FPV VP2 protein, a phage display nano antibody library is constructed, and two nano antibodies 3D6 and 1B9 with strong specificity and high affinity are obtained through multiple rounds of panning and identification. Through identification, the nano antibodies 3D6 and 1B9 can be specifically combined with FPV and VP2 proteins, and have high affinity and remarkable virus neutralizing activity. The nano antibody can be used for preparing a detection reagent or kit for feline parvovirus infection, and rapid and accurate diagnosis is realized; the compound can also be used as an active component to prepare a therapeutic drug, and provides a special therapeutic scheme for FPV infection. The nano antibody provides an important material basis for developing a novel diagnostic tool and a specific therapeutic drug aiming at the feline parvovirus.

The application aims to provide a Cystoseira low molecular weight polysaccharide and a preparation method and application thereof, which is prepared by fermentation of Cystoseira powder by Periconia sp. QAU-OG-Isz-15 with the preservation number of CGMCC No. 21455. The application effectively reduces the molecular weight of Cystoseira polysaccharide by microbial degradation, increases the content of functional polysaccharide, and further improves the anti-AD activity. In the in vitro experiment, compared with the undegraded Cystoseira polysaccharide, the Cystoseira low molecular weight polysaccharide has a more obvious inhibitory effect on Aβ 1‑42 aggregation, and in the C. elegans in vivo experiment, the Cystoseira low molecular weight polysaccharide has the effects of increasing the lifespan of C. elegans, delaying aging, and promoting the motor ability and reproductive ability of C. elegans, and has a significant inhibitory effect on Aβ 1‑42 aggregation. It is shown that the Cystoseira low molecular weight polysaccharide as a natural product ingredient has great potential in the development and application of new anti-AD therapeutic drugs and functional foods.

The application discloses a single-chain antibody, the amino acid sequence of which is shown as SEQ ID NO:1, and the nucleotide sequence of which is shown as SEQ ID NO:2. The single-chain antibody against rabies virus is screened from an antibody library of immunized mice by using a phage display technology. Compared with a traditional cell fusion technology, the phage display technology is simple in operation, low in cost, short in time, and high in antibody discovery and screening efficiency. The single-chain antibody obtained by the application is low in molecular weight and immunogenicity, high in antibody specificity and affinity, and has the activity of neutralizing rabies virus, thereby providing a new idea for basic research of rabies virus and development of therapeutic drugs.

The invention provides application of FOXL2 in preparation of a medicine for promoting differentiation or treating ovarian cancer. The FOXL2 action mechanism research with clearer and more complete evidence chain is carried out on the action of the FOXL2 in ovarian cancer, especially epithelial ovarian cancer by using large sample data, the effects of overexpression FOXL2 on tumor formation inhibition, differentiation promotion, metastasis inhibition and the like of ovarian cancer cells are effectively verified, and a new strategy is provided for treatment of ovarian cancer.

The invention discloses a gene therapy nose drop for preventing and / or treating coronavirus as well as preparation and application of the gene therapy nose drop, and belongs to the technical field of biological medicines. The nose drop comprises a reagent A and a reagent B. The reagent A is a nano-gene therapy drug solution connecting a self-assembled composite nano-material carrier and a targeted nucleic acid cleavage system through a click reaction, and the cleavage system comprises endonuclease molecules and an hpDNA oligonucleotide probe set. The hpDNA probe can target a coronavirus N gene conserved sequence and a host cell CtslmRNA at the same time through stem-loop structural design, can cut virus RNA to inhibit replication of the virus RNA, and can block the activation process of virus spike protein; the reagent B is an inhalable preparation of an anti-inflammatory chemical drug, and the drug absorption efficiency is remarkably improved by regulating inflammatory reaction. The nose drop can efficiently prevent and treat coronavirus infection and respiratory tract complications caused by the coronavirus infection through a triple mechanism of'gene editing-host regulation-anti-inflammatory treatment 'in combination with the advantage of nasal local administration, and has the obvious characteristics of high bioavailability and low system toxicity.

The invention discloses application of a series of extremely early stem cells or differentiated cell lineages thereof in preparation and detection of influenza viruses and drug screening, and belongs to the field of cell application. Specifically, trophoblast stem cells (TSC) and amnion-like stem cells (AME) obtained by extremely early cell induced differentiation and screening are used for influenza virus infection or screening test. Experiments prove that extraembryonic differentiation cell models such as trophoblast stem cells, amniotic stem cells and / or differentiated cell lineages thereof are highly susceptible to influenza viruses, and have important application values in the aspects of efficient preparation and detection of viruses and variants thereof, preparation of preventive vaccines and screening of therapeutic drugs. The method not only aims at human-derived influenza viruses and variants thereof, but also has important significance on prevention and treatment of animal influenza and variants thereof.